

James R Burke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4027789/publications.pdf>

Version: 2024-02-01

120
papers

15,829
citations

38660

50
h-index

22102

113
g-index

133
all docs

133
docs citations

133
times ranked

19391
citing authors

#	ARTICLE	IF	CITATIONS
1	Convolutional neural network to identify symptomatic Alzheimer's disease using multimodal retinal imaging. <i>British Journal of Ophthalmology</i> , 2022, 106, 388-395.	2.1	56
2	Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. <i>Scientific Reports</i> , 2022, 12, 6117.	1.6	12
3	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. <i>JAMA Neurology</i> , 2021, 78, 102.	4.5	144
4	Assessing the Retinal Microvasculature in Individuals With Early and Late-Onset Alzheimer's Disease. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2021, 52, 336-344.	0.4	5
5	Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 537-547.	4.9	55
6	Racial Differences in the Pathway to Diagnosis of Alzheimer's Disease and Related Dementias. <i>Innovation in Aging</i> , 2021, 5, 278-278.	0.0	0
7	Longer Term Effects of Diet and Exercise on Neurocognition: 1-Year Follow-up of the ENLIGHTEN Trial. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 559-568.	1.3	17
8	Metabolic and Neurocognitive Changes Following Lifestyle Modification: Examination of Biomarkers from the ENLIGHTEN Randomized Clinical Trial. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1793-1803.	1.2	8
9	How Accurately Do Patients and Their Care Partners Report Results of Amyloid- β PET Scans for Alzheimer's Disease Assessment?. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 625-636.	1.2	11
10	Association of OCT Angiography Parameters With Age in Cognitively Healthy Older Adults. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2020, 51, 706-714.	0.4	6
11	Effects of pioglitazone on mnemonic hippocampal function: A blood oxygen level-dependent functional magnetic resonance imaging study in elderly adults. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 254-263.	1.8	10
12	Association Between Insulin Resistance, Plasma Leptin, and Neurocognition in Vascular Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 921-929.	1.2	13
13	Retinal Microvascular and Neurodegenerative Changes in Alzheimer's Disease and Mild Cognitive Impairment Compared with Control Participants. <i>Ophthalmology Retina</i> , 2019, 3, 489-499.	1.2	151
14	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
15	DTA-02: TOMMORROW: RESULTS FROM A PHASE 3 TRIAL TO DELAY THE ONSET OF MCI DUE TO AD AND QUALIFY A GENETIC BIOMARKER ALGORITHM. <i>Alzheimer's and Dementia</i> , 2019, 15, P1488.	0.4	3
16	Lifestyle and neurocognition in older adults with cognitive impairments. <i>Neurology</i> , 2019, 92, e212-e223.	1.5	71
17	Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 834.	4.5	136
18	Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 595-598.	1.2	2

#	ARTICLE	IF	CITATIONS
19	Sex-specific genetic predictors of Alzheimer's disease biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 857-872.	3.9	87
20	Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. <i>JAMA Neurology</i> , 2018, 75, 989.	4.5	223
21	Evaluation of inner retinal layers as biomarkers in mild cognitive impairment to moderate Alzheimer's disease. <i>PLoS ONE</i> , 2018, 13, e0192646.	1.1	88
22	A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/A β 42 cutoff with concordance to amyloid positron emission tomography imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 201-209.	1.2	19
23	Transethnic genome-wide scan identifies novel Alzheimer's disease loci. <i>Alzheimer's and Dementia</i> , 2017, 13, 727-738.	0.4	166
24	Lifestyle and Neurocognition in Older Adults With Cardiovascular Risk Factors and Cognitive Impairment. <i>Psychosomatic Medicine</i> , 2017, 79, 719-727.	1.3	29
25	Rare coding variants in <i>PLCG2</i> , <i>ABI3</i> , and <i>TREM2</i> implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
26	[P3548]: METALAXYL MAY BE ASSOCIATED WITH DECREASED COGNITIVE FUNCTION IN OLDER PESTICIDE APPLICATORS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1188.	0.4	0
27	P3369: Design of the Agricultural Health Study of Memory in Aging. <i>Alzheimer's and Dementia</i> , 2016, 12, P990.	0.4	1
28	Assessment of the genetic variance of late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 41, 200.e13-200.e20.	1.5	174
29	Prefrontal contributions to relational encoding in amnesic mild cognitive impairment. <i>NeuroImage: Clinical</i> , 2016, 11, 158-166.	1.4	5
30	Epigenetic assimilation in the aging human brain. <i>Genome Biology</i> , 2016, 17, 76.	3.8	43
31	A genetics-based biomarker risk algorithm for predicting risk of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 30-44.	1.8	26
32	A Plan for Academic Biobank Solvency—Leveraging Resources and Applying Business Processes to Improve Sustainability. <i>Clinical and Translational Science</i> , 2015, 8, 553-557.	1.5	6
33	Stability of Diagnoses of Cognitive Impairment, Not Dementia in a Veterans Affairs Primary Care Population. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1105-1111.	1.3	7
34	Rarity of the Alzheimer Disease—Protective <i>APP</i> A673T Variant in the United States. <i>JAMA Neurology</i> , 2015, 72, 209.	4.5	41
35	P4-242: A case-control cohort study to define a threshold for the tau/abeta42 ratio in cerebrospinal fluid optimized for diagnosis of Alzheimer's disease. , 2015, 11, P873-P873.		0
36	Factors associated with cognitive evaluations in the United States. <i>Neurology</i> , 2015, 84, 64-71.	1.5	82

#	ARTICLE	IF	CITATIONS
37	Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals. <i>JAMA Neurology</i> , 2015, 72, 1313.	4.5	39
38	Impact of ¹⁸ F-florbetapir PET imaging of β^2 -amyloid neuritic plaque density on clinical decision-making. <i>Neurocase</i> , 2014, 20, 466-473.	0.2	19
39	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1394.	4.5	166
40	Pre-clinical Cognitive Phenotypes for Alzheimer Disease: A Latent Profile Approach. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1364-1374.	0.6	18
41	Alzheimer's Disease, Anesthesia, and Surgery: A Clinically Focused Review. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2014, 28, 1609-1623.	0.6	39
42	The cis-regulatory effect of an Alzheimer's disease-associated polycomb locus on expression of TOMM40 and apolipoprotein E genes. <i>Alzheimer's and Dementia</i> , 2014, 10, 541-551.	0.4	73
43	O4-07-01: EFFECTS OF PIOGLITAZONE ON MNEMONIC HIPPOCAMPAL FUNCTION: A PHARMACOLOGIC BOLD FMRI STUDY IN HEALTHY ELDERLY SUBJECTS. , 2014, 10, P263-P263.		0
44	Can lifestyle modification improve neurocognition? Rationale and design of the ENLIGHTEN clinical trial. <i>Contemporary Clinical Trials</i> , 2013, 34, 60-69.	0.8	18
45	Neuropsychological Predictors of Dementia in Late-Life Major Depressive Disorder. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 297-306.	0.6	41
46	Phenotypic regional functional imaging patterns during memory encoding in mild cognitive impairment and Alzheimer's disease. , 2013, 9, 284-294.		48
47	Inhibition of Protein Misfolding/Aggregation Using Polyglutamine Binding Peptide QBP1 as a Therapy for the Polyglutamine Diseases. <i>Neurotherapeutics</i> , 2013, 10, 440-446.	2.1	30
48	Using Genetics to Enable Studies on the Prevention of Alzheimer's Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 177-185.	2.3	67
49	Event-Related Functional Magnetic Resonance Imaging Changes during Relational Retrieval in Normal Aging and Amnesic Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2012, 18, 886-897.	1.2	11
50	An international perspective on advanced neuroimaging: cometh the hour or ivory tower? " CORRIGENDUM. <i>International Psychogeriatrics</i> , 2012, 24, 170-170.	0.6	0
51	The Alzheimer's associated 5' region of the SORL1 gene cis regulates SORL1 transcripts expression. <i>Neurobiology of Aging</i> , 2012, 33, 1485.e1-1485.e8.	1.5	18
52	Novel late-onset Alzheimer disease loci variants associate with brain gene expression. <i>Neurology</i> , 2012, 79, 221-228.	1.5	144
53	Sound Induced Vertigo: Superior Canal Dehiscence Resulting From Blast Exposure. <i>Archives of Physical Medicine and Rehabilitation</i> , 2012, 93, 723-724.	0.5	4
54	Screening for Cognitive Impairment: Comparing the Performance of Four Instruments in Primary Care. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 1027-1036.	1.3	96

#	ARTICLE	IF	CITATIONS
55	Metabolomic changes in autopsy-confirmed Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 309-317.	0.4	132
56	The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases. <i>Journal of Amino Acids</i> , 2011, 2011, 1-10.	5.8	20
57	An international perspective on advanced neuroimaging: cometh the hour or ivory tower?. <i>International Psychogeriatrics</i> , 2011, 23, S58-S64.	0.6	3
58	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 436-441.	9.4	1,676
59	The effect of SNCA 3' region on the levels of SNCA-112 splicing variant. <i>Neurogenetics</i> , 2011, 12, 59-64.	0.7	54
60	Incidence of dementia and cognitive impairment, not dementia in the united states. <i>Annals of Neurology</i> , 2011, 70, 418-426.	2.8	199
61	Temporoparietal Hypometabolism in Frontotemporal Lobar Degeneration and Associated Imaging Diagnostic Errors. <i>Archives of Neurology</i> , 2011, 68, 329-37.	4.9	71
62	Risk Factors and Preventive Interventions for Alzheimer Disease. <i>Archives of Neurology</i> , 2011, 68, 1185.	4.9	234
63	Metabolomics in Early Alzheimer's Disease: Identification of Altered Plasma Sphingolipidome Using Shotgun Lipidomics. <i>PLoS ONE</i> , 2011, 6, e21643.	1.1	367
64	Validation of Consensus Panel Diagnosis in Dementia. <i>Archives of Neurology</i> , 2010, 67, 1506-12.	4.9	30
65	Genome-Wide Scan of Copy Number Variation in Late-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 69-77.	1.2	118
66	Systematic Review: Factors Associated With Risk for and Possible Prevention of Cognitive Decline in Later Life. <i>Annals of Internal Medicine</i> , 2010, 153, 182.	2.0	552
67	Twin pairs discordant for neuropathologically confirmed Lewy body dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 562-565.	0.9	20
68	Cognitive performance and informant reports in the diagnosis of cognitive impairment and dementia in African Americans and whites. <i>Alzheimer's and Dementia</i> , 2009, 5, 445-453.	0.4	155
69	Cerebrovascular Smooth Muscle Actin Is Increased in Nondemented Subjects With Frequent Senile Plaques at Autopsy: Implications for the Pathogenesis of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 417-424.	0.9	5
70	Genetic Regulation of α -Synuclein mRNA Expression in Various Human Brain Tissues. <i>PLoS ONE</i> , 2009, 4, e7480.	1.1	77
71	Pathogenesis of Inclusion Bodies in (CAG) _n /Qn-Expansion Diseases with Special Reference to the Role of Tissue Transglutaminase and to Selective Vulnerability. <i>Journal of Neurochemistry</i> , 2008, 72, 889-899.	2.1	66
72	A novel human disease with abnormal prion protein sensitive to protease. <i>Annals of Neurology</i> , 2008, 63, 697-708.	2.8	250

#	ARTICLE	IF	CITATIONS
73	Identification of Chemical Inhibitors to Human Tissue Transglutaminase by Screening Existing Drug Libraries. <i>Chemistry and Biology</i> , 2008, 15, 969-978.	6.2	59
74	Midlife activity predicts risk of dementia in older male twin pairs. <i>Alzheimer's and Dementia</i> , 2008, 4, 324-331.	0.4	136
75	Neuroanatomical correlates of malingered memory impairment: Event-related fMRI of deception on a recognition memory task. <i>Brain Injury</i> , 2008, 22, 481-489.	0.6	44
76	Prevalence of Cognitive Impairment without Dementia in the United States. <i>Annals of Internal Medicine</i> , 2008, 148, 427.	2.0	758
77	Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study. <i>Neuroepidemiology</i> , 2007, 29, 125-132.	1.1	1,622
78	Arteriolar ApoE expression is increased Alzheimer disease cortex. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 433.	0.9	0
79	Postmortem Delay Has Minimal Effect on Brain RNA Integrity. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 1093-1099.	0.9	51
80	Job demands and dementia risk among male twin pairs. , 2007, 3, 192-199.		36
81	Alternative ion channel splicing in mesial temporal lobe epilepsy and Alzheimer's disease. <i>Genome Biology</i> , 2007, 8, R32.	13.9	38
82	Optimization of a Polyglutamine Aggregation Inhibitor Peptide (QBP1) Using a Thioflavin T Fluorescence Assay. <i>Assay and Drug Development Technologies</i> , 2007, 5, 629-636.	0.6	11
83	Longitudinal Magnetic Resonance Imaging Vascular Changes, Apolipoprotein E Genotype, and Development of Dementia in the Neurocognitive Outcomes of Depression in the Elderly Study. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 839-849.	0.6	92
84	Comparison of clinical and neuropathologic diagnoses of Alzheimer's disease in 3 epidemiologic samples. , 2006, 2, 2-11.		42
85	Polyglutamine expansion inhibits respiration by increasing reactive oxygen species in isolated mitochondria. <i>Biochemical and Biophysical Research Communications</i> , 2006, 341, 607-613.	1.0	37
86	Phage Display Screening for Peptides that Inhibit Polyglutamine Aggregation. <i>Methods in Enzymology</i> , 2006, 413, 253-273.	0.4	3
87	Duke Twins Study of Memory in Aging in the NAS-NRC Twin Registry. <i>Twin Research and Human Genetics</i> , 2006, 9, 950-957.	0.3	22
88	Duke Twins Study of Memory in Aging in the NAS-NRC Twin Registry. <i>Twin Research and Human Genetics</i> , 2006, 9, 950-7.	0.3	21
89	Emotional enhancement of perceptual priming is preserved in aging and early-stage Alzheimer's disease. <i>Neuropsychologia</i> , 2005, 43, 1824-1837.	0.7	39
90	The Aging, Demographics, and Memory Study: Study Design and Methods. <i>Neuroepidemiology</i> , 2005, 25, 181-191.	1.1	317

#	ARTICLE	IF	CITATIONS
91	Population-Based Study of Medical Comorbidity in Early Dementia and "Cognitive Impairment, No Dementia (CIND)": Association With Functional and Cognitive Impairment: The Cache County Study. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 656-664.	0.6	76
92	Methodology and Preliminary Results From the Neurocognitive Outcomes of Depression in the Elderly Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004, 17, 202-211.	1.2	85
93	Disrupted Spermine Homeostasis: A Novel Mechanism in Polyglutamine-Mediated Aggregation and Cell Death. <i>Journal of Neuroscience</i> , 2004, 24, 7118-7127.	1.7	19
94	APOE genotype-specific differences in human and mouse macrophage nitric oxide production. <i>Journal of Neuroimmunology</i> , 2004, 147, 62-67.	1.1	74
95	Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats. <i>Journal of Neurochemistry</i> , 2004, 88, 1253-1260.	2.1	49
96	P4-137 Alzheimer's disease in the NAS-NRC twin registry of WWII veterans. <i>Neurobiology of Aging</i> , 2004, 25, S514.	1.5	4
97	Disruption of the toxic conformation of the expanded polyglutamine stretch leads to suppression of aggregate formation and cytotoxicity. <i>Biochemical and Biophysical Research Communications</i> , 2004, 317, 1200-1206.	1.0	26
98	In vitro effects of polyglutamine tracts on Ca ²⁺ -dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. <i>Archives of Biochemistry and Biophysics</i> , 2003, 410, 1-6.	1.4	94
99	Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in <i>Drosophila</i> . <i>Human Molecular Genetics</i> , 2003, 12, 1253-1259.	1.4	122
100	Expanded polyglutamine stretches form an "aggresome". <i>Neuroscience Letters</i> , 2002, 323, 215-218.	1.0	41
101	Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. <i>Nature Neuroscience</i> , 2002, 5, 731-736.	7.1	925
102	Amino Acid Sequence Requirements of Peptides That Inhibit Polyglutamine-Protein Aggregation and Cell Death. <i>Biochemical and Biophysical Research Communications</i> , 2001, 288, 703-710.	1.0	36
103	Inhibition of Polyglutamine Protein Aggregation and Cell Death by Novel Peptides Identified by Phage Display Screening. <i>Journal of Biological Chemistry</i> , 2000, 275, 10437-10442.	1.6	166
104	Generation of Neuronal Intranuclear Inclusions by Polyglutamine-GFP: Analysis of Inclusion Clearance and Toxicity as a Function of Polyglutamine Length. <i>Journal of Neuroscience</i> , 1999, 19, 705-715.	1.7	89
105	Polyglutamine Domain Proteins with Expanded Repeats Bind Neurofilament, Altering the Neurofilament Network. <i>Annals of the New York Academy of Sciences</i> , 1999, 893, 192-201.	1.8	10
106	Expanded Polyglutamine Domain Proteins Bind Neurofilament and Alter the Neurofilament Network. <i>Experimental Neurology</i> , 1999, 155, 195-203.	2.0	21
107	Update on Alzheimer's disease. <i>Postgraduate Medicine</i> , 1999, 106, 85-96.	0.9	32
108	Managing common behavioral problems in dementia. <i>Postgraduate Medicine</i> , 1999, 106, 131-140.	0.9	20

#	ARTICLE	IF	CITATIONS
109	Inhibition of α -ketoglutarate-and pyruvate dehydrogenase complexes in E. coli by a glutathione S-transferase containing a pathological length poly-Q domain: A possible role of energy deficit in neurological diseases associated with poly-Q expansions?. <i>Age</i> , 1998, 21, 25-30.	3.0	3
110	Glyceraldehyde 3-Phosphate Dehydrogenase Abnormality in Metabolically Stressed Huntington Disease Fibroblasts. <i>Developmental Neuroscience</i> , 1998, 20, 462-468.	1.0	25
111	Oligomerization of Expanded-Polyglutamine Domain Fluorescent Fusion Proteins in Cultured Mammalian Cells. <i>Biochemical and Biophysical Research Communications</i> , 1997, 238, 599-605.	1.0	64
112	Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and α -ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 12604-12609.	3.3	92
113	Polyglutamine Domains Are Substrates of Tissue Transglutaminase: Does Transglutaminase Play a Role in Expanded CAG/Poly-Q Neurodegenerative Diseases?. <i>Journal of Neurochemistry</i> , 1997, 69, 431-434.	2.1	84
114	Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. <i>Lancet, The</i> , 1996, 348, 90-93.	6.3	246
115	Toxicity of expanded polyglutamine-domain proteins in Escherichia coli. <i>FEBS Letters</i> , 1996, 399, 135-139.	1.3	44
116	Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. <i>Nature Medicine</i> , 1996, 2, 347-350.	15.2	429
117	Reply to "A role for GAPDH in apoptosis and neurodegeneration". <i>Nature Medicine</i> , 1996, 2, 610-610.	15.2	2
118	The Haw River Syndrome: Dentatorubropallidoluysian atrophy (DRPLA) in an African-American family. <i>Nature Genetics</i> , 1994, 7, 521-524.	9.4	228
119	Dentatorubral-pallidoluysian atrophy and Haw River syndrome. <i>Lancet, The</i> , 1994, 344, 1711-1712.	6.3	39
120	Neuropsychological Detection of Preclinical Alzheimer's Disease: Results of a Neuropathological Series of "Normal" Controls. , 0, , 111-122.		0